Taimed forced to respond to more press speculation todaySeems like growing interest in Taimed.
Google translate
2. Company Name: Zhongyu New Drug Co., Ltd. 3. And the company (please enter the company or subsidiary): The Company
4. Mutual shareholding ratio: not applicable
5. Media name: 1101 issue of this week's P.69
6. Report content:
"One-year sales of Zhongyu TMB-355, equivalent to NT $ 3.6 billion" "Estimated by the fact that Zhongyu's share capital is only RMB2.5 billion,
TMB-355 This medicine, if reached the sales peak, has the potential to contribute to more than five yuan of profit. "
7. Reasons: This week's report about the pharmaceutical sales and earnings per share forecast
8. Response measures:
The Company has never made any sales and earnings per share forecast, the media reports on the media speculation, the new drug in the margin
Relevant information is based on "public information observatory" announcement shall prevail.
9. Other matters that should be stated:
The long duration of development of new drugs, the high cost of inputs and the failure to guarantee certain success will likely put the investment at risk,
Investors should exercise caution in judicious investment.